Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 6, 2011, Pages 1301-1307

  Haines, Melissa L ^a   Ajlouni, Yousef ^a   Irving, Peter M ^a   Sparrow, Miles P ^a   Rose, Rosemary ^a   Gearry, Richard B ^a   Gibson, Peter R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

6 mercaptopurine; azathioprine; inflammatory bowel disease; metabolite; therapeutic drug monitoring; thiopurine

Indexed keywords

6 METHYL MERCAPTOPURINE; 6 THIOGUANINE NUCLEOTIDE; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL LYSATE; CROHN DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG UNDERDOSE; ENTERITIS; ERYTHROCYTE; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT REFUSAL; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; THIOGUANINE; TREATMENT FAILURE; YOUNG ADULT;

EID: 79955828365     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21458     Document Type: Article

References (34)

1. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50: 485-489. (Pubitemid 34638866)
2. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995; 123: 132-142.
3. Pearson DC, May GR, Fick G, et al. Azathioprine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2000: CD000067.
4. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004; 13: 563-567. (Pubitemid 39214035)
5. Lennard L, Singleton HJ,. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992; 583: 83-90.
6. Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol. 2003; 38: 972-977. (Pubitemid 37153627)
7. Paerregaard A, Schmiegelow K,. Monitoring azathioprine metabolite levels and thiopurine methyl transferase (TPMT) activity in children with inflammatory bowel disease. Scand J Gastroenterol. 2002; 37: 371-372. (Pubitemid 34194828)
8. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001; 36: 71-76. (Pubitemid 32147184)
9. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996; 39: 401-406. (Pubitemid 26338529)
10. Cuffari C, Hunt S, Bayless T,. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001; 48: 642-646. (Pubitemid 32378583)
11. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000; 118: 705-713. (Pubitemid 30171620)
12. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut. 2004; 53: 1123-1128. (Pubitemid 38961966)
13. Hindorf U, Lyrenas E, Nilsson A, et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39: 1105-1112. (Pubitemid 39536400)
14. Ooi CY, Bohane TD, Lee D, et al. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25: 941-947. (Pubitemid 46525340)
15. Dubinsky MC,. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2003; 5: 506-511. (Pubitemid 38915051)
16. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004; 26: 311-318. (Pubitemid 38703020)
17. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122: 904-915. (Pubitemid 34267273)
18. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007; 5: 209-214. (Pubitemid 46216945)
19. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005; 22: 441-446. (Pubitemid 41248111)
20. Gearry RB, Barclay ML,. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005; 20: 1149-1157. (Pubitemid 41602556)
21. Gardiner SJ, Gearry RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008; 6: 654-660; quiz 604.
22. Bloomfeld RS, Onken JE,. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther. 2003; 17: 69-73. (Pubitemid 36140436)
23. Cohen RD,. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy." Gastroenterology. 2002; 122: 2082-2084; discussion 2084.
24. Siegel CA, Sands BE,. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005; 22: 1-16. (Pubitemid 40943869)
25. Sandborn WJ,. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporin and methotrexate. Am J Gastroenterol. 1996; 91: 423-433. (Pubitemid 126733803)
26. Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J. 2005; 35: 580-585. (Pubitemid 41564403)
27. Gilissen LP, Derijks LJ, Bos LP, et al. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Invest. 2004; 24: 479-486. (Pubitemid 39128014)
28. Leong RW, Gearry RB, Sparrow MP,. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf. 2008; 7: 607-616.
29. Morales A, Salguti S, Miao CL, et al. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 380-385. (Pubitemid 46668241)
30. Gardiner SJ, Gearry RB, Burt MJ, et al. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol. 2008; 20: 1238-1242.
31. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100: 2239-2247.
32. Waljee AK, Joyce JC, Wang S, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol. 2010; 8: 143-150.
33. D'Halluin PN, Tribut O, Branger B, et al. RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol Clin Biol. 2005; 29: 1264-1269. (Pubitemid 43170258)
34. Andrews JM, Travis SPL, Gibson PR, et al. Systematic review: concurrent therapy with 5-ASA and immunomodulators in IBD. Aliment Pharmacol Ther. 2009; 9: 459-369.